[go: up one dir, main page]

AU2002220038A1 - Immunomodulatory peptides derived from heat shock proteins and uses thereof - Google Patents

Immunomodulatory peptides derived from heat shock proteins and uses thereof

Info

Publication number
AU2002220038A1
AU2002220038A1 AU2002220038A AU2003802A AU2002220038A1 AU 2002220038 A1 AU2002220038 A1 AU 2002220038A1 AU 2002220038 A AU2002220038 A AU 2002220038A AU 2003802 A AU2003802 A AU 2003802A AU 2002220038 A1 AU2002220038 A1 AU 2002220038A1
Authority
AU
Australia
Prior art keywords
peptide
seq
subject
dnaj
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220038A
Other languages
English (en)
Inventor
Salvatore Albani
Dennis A. Carson
Alberto Martini
Berent J. Prakken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2002220038A1 publication Critical patent/AU2002220038A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002220038A 2000-11-01 2001-10-31 Immunomodulatory peptides derived from heat shock proteins and uses thereof Abandoned AU2002220038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24518100P 2000-11-01 2000-11-01
US60/245,181 2000-11-01
PCT/US2001/045344 WO2002036611A2 (fr) 2000-11-01 2001-10-31 Peptides immunomodulateurs derives de proteines de choc thermique et leur utilisations

Publications (1)

Publication Number Publication Date
AU2002220038A1 true AU2002220038A1 (en) 2002-05-15

Family

ID=22925623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220038A Abandoned AU2002220038A1 (en) 2000-11-01 2001-10-31 Immunomodulatory peptides derived from heat shock proteins and uses thereof

Country Status (13)

Country Link
US (2) US7301005B2 (fr)
EP (1) EP1355923B1 (fr)
JP (1) JP4264257B2 (fr)
KR (1) KR20030055295A (fr)
CN (1) CN1481390B (fr)
AT (1) ATE548376T1 (fr)
AU (1) AU2002220038A1 (fr)
BR (1) BR0115246A (fr)
CA (1) CA2427572A1 (fr)
EA (1) EA005821B1 (fr)
IL (1) IL155610A0 (fr)
MX (1) MXPA03003901A (fr)
WO (1) WO2002036611A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052773A2 (fr) * 2004-11-07 2006-05-18 Androclus Therapeutics Inc. Traitement pour des affections demyelinisantes a mediation immunitaire
WO2007140287A2 (fr) * 2006-05-25 2007-12-06 Dr. Reddy's Laboratories, Inc. Utilisation de biomarqueurs d'inflammation en tant qu'indicateurs d'efficacité d'un médicament
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
JP2010532785A (ja) 2007-07-06 2010-10-14 ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ． 炎症性疾患および自己免疫疾患の治療および予防
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
RU2483746C1 (ru) * 2012-05-17 2013-06-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Средство для антиагрегатной, антивоспалительной и цитопротекторной терапии
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
KR20190028662A (ko) 2016-05-25 2019-03-19 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역요법의 방법
AR114683A1 (es) * 2018-02-09 2020-10-07 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Polipéptidos inmunomoduladores e inmunoestimulantes para suministro de drogas
GB201807831D0 (en) * 2018-05-15 2018-06-27 Univ College Cardiff Consultants Ltd Cancer Vaccine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732757A (en) 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
US4683295A (en) 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4654419A (en) 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US5116725A (en) 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
WO1990014835A1 (fr) 1989-05-31 1990-12-13 Scripps Clinic And Research Foundation Procede permettant de traiter le rhumatisme articulaire
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
JPH10500679A (ja) 1994-05-20 1998-01-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 慢性関節リウマチを治療するための方法および試薬
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
DE19702065C1 (de) * 1997-01-22 1998-05-20 Kurzik Dumke Ursula Dr Polyklonaler Antikörper zum Nachweis des tumorassoziierten Antigens hTid
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5992567A (en) 1999-01-29 1999-11-30 Chiu; Ping-Jan Foldable frame

Also Published As

Publication number Publication date
IL155610A0 (en) 2003-11-23
US7301005B2 (en) 2007-11-27
WO2002036611A3 (fr) 2003-08-21
EP1355923B1 (fr) 2012-03-07
BR0115246A (pt) 2005-04-26
KR20030055295A (ko) 2003-07-02
US20030031679A1 (en) 2003-02-13
CA2427572A1 (fr) 2002-05-10
EA200300438A1 (ru) 2003-12-25
JP4264257B2 (ja) 2009-05-13
EA005821B1 (ru) 2005-06-30
ATE548376T1 (de) 2012-03-15
EP1355923A2 (fr) 2003-10-29
WO2002036611A2 (fr) 2002-05-10
CN1481390A (zh) 2004-03-10
MXPA03003901A (es) 2004-09-10
JP2004537496A (ja) 2004-12-16
CN1481390B (zh) 2010-12-22
US20080187550A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
US20080187550A1 (en) Immunomodulatory Peptides Derived from Heat Shock Proteins and Uses Thereof
Wendling et al. A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue
AU2009321481B2 (en) Compositions and methods for treatment of celiac disease
JP3100005B2 (ja) ヒト免疫不全ウィルス感染・増殖抑制剤
US5773573A (en) HIV peptides
AU758576B2 (en) Chemokines with amino-terminal modifications
JP2020504161A (ja) 結核菌シャペロニン６０．１ペプチドおよびその使用
US20160024183A1 (en) Synthetic peptides for the treatment of autoimmune diseases
IL105153A (en) Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
AU2001285427A1 (en) Stress proteins and peptides and methods of use thereof
WO2002012286A2 (fr) Proteines et peptides du stress et methodes d'utilisation
AU2018274876A1 (en) Compositions and methods for treatment of celiac disease
US20230416318A1 (en) Osteoanabolism by 14-3-3zeta
AU2008200490A1 (en) Immunomodulatory peptides derived from heat shock proteins and uses thereof
CN101602793A (zh) 用于预防和/或治疗类风湿性关节炎的免疫调节多肽及其应用
Kalidas Protein engineering studies of beta-lactoglobulin expressed in Pichia pastoris
EP1652856A1 (fr) Peptides dérivés de protéines de stress et méthodes d'utilisation
WO2005040208A2 (fr) Molecules pour moduler l'activite des recepteurs de type toll et procedes d'utilisation associes
WO2010065157A2 (fr) Fragments de pepsine inactivés pour moduler l'activité du système immun contre des cellules tumorales malignes humaines
HK1089455A (en) Stress proteins-derived peptides and method of use thereof
HK1022918A1 (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted